Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

ABSTRACT:

Aims

To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus.

Methods

Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration.

Results

This study comprised 3300 patients (cohort 1, N = 823; cohort 2, N = 2477). Empagliflozin reduced weight, waist circumference and adiposity indices versus placebo in both cohorts. Adjusted mean (95% confidence interval) c

SUBMITTER: Neeland IJ 

PROVIDER: S-EPMC4768401 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature